Table 2.

IC₅₀ values obtained by proliferation assay for AP26113, ASP3026, alectinib and ceritinib against parental, Ba/F3 NPM-ALK WT, EML4-ALK WT, and mutated cells are reported

Cell lines	IC50 (μmol/L)
	AP26113	ASP3026	Alectinib	Ceritinib
Ba/F3	>1	5.964	>10	>1
Ba/F3 NA WT	0.011	0.084	0.020	0.020
Ba/F3 NA C1156Y	0.016	0.284	0.038	0.071
Ba/F3 NA L1196M	0.030	0.682	0.032	0.042
Ba/F3 NA L1152R	0.004	2.763	0.047	0.288
Ba/F3 NA G1202R	0.149	1.177	0.549	0.277
Ba/F3 NA G1269A	0.011	0.364	0.104	0.019
Ba/F3 NA S1206Y	0.022	0.110	0.025	0.037
Ba/F3	>1	5.964	>10	>1
Ba/F3 EA WT	0.006	0.056	0.013	0.021
Ba/F3 EA C1156Y	0.005	0.090	0.010	0.026
Ba/F3 EA L1196M	0.008	0.141	0.022	0.019
Ba/F3 EA L1152R	0.001	0.514	0.017	0.099
Ba/F3 EA G1202R	0.325	1.210	0.868	0.467
Ba/F3 EA G1269A	0.009	0.118	0.084	0.033
Ba/F3 EA S1206Y	0.021	0.118	0.037	0.038

¹IC₅₀, half maximal inhibitory concentration; NPM, nucleophosmin; ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein-like 4; WT, wild type.